CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter TrialNirali N. Shah, Richard Aplenc, Anthony Welch et al.|Blood|2023Cited by 62
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapyEmily M. Hsieh, Regina M. Myers, Bonnie Yates et al.|Blood Advances|2022Cited by 34
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemiaSara Silbert, Marlie R. M. Provost, Alexander W. Rankin et al.|Blood|2025Cited by 33
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adultsAdam J. Lamble, Shannon L. Maude, Liora M. Schultz et al.|Blood Advances|2024Cited by 32
INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent ToxicitiesKevin O. McNerney, Jenna Rossoff, Emily M. Hsieh et al.|Transplantation and Cellular Therapy|2023Cited by 20